Assertio Therapeutics Announces Third-Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Assertio Therapeutics (ASRT) Reports In-Line Q3 EPS; Raises Outlook
November 6, 2019 5:15 PM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.24, in-line with the analyst estimate of $0.24. Revenue for the quarter came in at $55.1 million versus the consensus estimate of $60.74 million.
We reported another quarter of strong earnings growth, exceeding non-GAAP adjusted EBITDA expectations... More
